Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter.
OBJECTIVE
The relationship between adding aprotinin to standard care and the frequency of postoperative atrial fibrillation or flutter (POAF) in patients undergoing cardiothoracic surgery (CTS) with cardiopulmonary bypass (CPB) was studied.


METHODS
This was a retrospective cohort evaluation. All patients at a hospital who underwent CTS with CPB between October 1999 and October 2003 and who received aprotinin during surgery were included in the treatment group. Control patients were those who did not receive aprotinin; they were matched with treatment group patients for age, valvular surgery, history of atrial fibrillation or flutter, renal dysfunction, peripheral artery disease, smoking, angina, diabetes mellitus, congestive heart failure, previous CTS, sex, beta-blocker intolerance, and use of preoperative digoxin. The primary endpoint was POAF; secondary endpoints were perioperative transfusion use, length of stay (LOS), stroke, myocardial infarction, renal failure, graft occlusion, and death.


RESULTS
A total of 438 patients (219 per group) were evaluated. The patients' mean age was 68 years, 67% were men, and 74% had had valvular surgery. Patients who received aprotinin (mean +/- S.D. dose, 2.75 million +/- 1.24 million kallikrein-inhibiting units) did not have a significantly lower frequency of POAF than control patients (28% versus 27%, respectively [p = 0.92]), nor was there a significant difference in secondary endpoints.


CONCLUSIONS
Aprotinin therapy was not associated with a significant reduction in POAF in patients undergoing CTS with CPB. Perioperative transfusion use, LOS, stroke, myocardial infarction, renal failure, graft occlusion, and mortality also did not differ significantly between aprotinin and control groups.
Gillespie
Effie L
EL
School of Pharmacy, University of Connecticut (UC), Storrs, USA.
Gryskiewicz
Kristen A
KA
White
C Michael
CM
Kluger
Jeffrey
J
Humphrey
Chester
C
Horowitz
Sheryl
S
Coleman
Craig I
CI
D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control*; D001282:Atrial Flutter / Q000209:etiology / Q000517:prevention & control*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D012189:Retrospective Studies; D013903:Thoracic Surgery; D014481:United States / Q000453:epidemiology
D007611:Aprotinin